Navigation Links
Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds

MADISON, N.J., Feb. 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today the end of its collaboration agreements with Solvay Pharmaceuticals for the development and commercialization of bifeprunox as well as other compounds in earlier stages of development for the potential treatment of schizophrenia and other psychiatric conditions.

Wyeth terminated the collaboration with Solvay after assessing the opportunity for bifeprunox and determining it would not have sufficient commercial value for the two companies to share.

All development and commercialization rights in North America for bifeprunox, an investigational atypical antipsychotic, as well as global rights for the other compounds will now revert to Solvay Pharmaceuticals.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and our pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors." The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Announces Executive Change in Finance Organization
2. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
3. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
5. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
6. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
9. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
10. Wyeth Declares Preferred Stock Dividend
11. Wyeth Announces Election of New Principal Corporate Officer
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), ... MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing ... AMA members have embraced this type of racing and several new model aviation pilots ...
(Date:11/24/2015)... , November 24, 2015 ... recent market research report released by Transparency Market Research, ... expand at a CAGR of 17.5% during the period ... Testing Market - Global Industry Analysis, Size, Volume, Share, ... global non-invasive prenatal testing market to reach a valuation ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series ... Warrants") subject to the previously disclosed November 1, ... which will result in the issuance of 365,518 ... issuance of such shares, there will be approximately ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the environment are paramount. Insertion points for in-line sensors can represent a weak ... the InTrac 781/784 series of retractable sensor housings , which are designed ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has ... of MIT and Harvard for use of its ... information management tools. The partnership will support the ... biological and chemical research information internally and with ... be used for managing the Institute,s electronic laboratory ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):